Published in PLoS One on December 28, 2010
Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis. Leukemia (2011) 1.43
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin Cancer Res (2016) 0.79
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin Cancer Res (2016) 0.77
Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. Leuk Lymphoma (2017) 0.75
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell (2001) 8.99
Brca1 controls homology-directed DNA repair. Mol Cell (1999) 7.82
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell (1984) 6.78
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell (1999) 5.28
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 5.20
How the fanconi anemia pathway guards the genome. Annu Rev Genet (2009) 4.94
S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood (2002) 4.27
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer (2007) 3.63
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1984) 3.24
Centrosome amplification, chromosome instability and cancer development. Cancer Lett (2005) 3.24
Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76
BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol (2004) 2.46
Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature (1976) 2.24
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood (2006) 2.18
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 1.98
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood (2004) 1.95
BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood (2001) 1.90
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med (2000) 1.89
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A (2003) 1.80
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol (1991) 1.68
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood (1994) 1.68
Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J (2007) 1.65
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
The Fanconi anemia pathway of genomic maintenance. Cell Oncol (2006) 1.52
BRCA1-independent ubiquitination of FANCD2. Mol Cell (2003) 1.46
AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res (2008) 1.35
Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol (2004) 1.32
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol (2000) 1.31
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood (1995) 1.30
A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. J Med Genet (2006) 1.30
BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia (2008) 1.21
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia (2005) 1.21
Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. Mol Cell (2008) 1.19
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res (2008) 1.17
Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem (1999) 1.15
Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood (1995) 1.13
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood (2003) 1.13
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood (2009) 1.13
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia (2010) 1.11
Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett (2005) 1.10
BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene (1998) 0.99
BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia (2008) 0.96
Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J Biol Chem (2010) 0.95
Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia (2004) 0.94
Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood (2002) 0.89
Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol (2008) 0.89
A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. Hum Gene Ther (2006) 0.84
BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br J Haematol (2008) 0.82
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature (2009) 5.37
Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet (2006) 5.12
A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood (2002) 4.59
The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet (2005) 4.13
Mutations of the SLX4 gene in Fanconi anemia. Nat Genet (2011) 3.60
Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet (2010) 3.57
Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem (2002) 3.27
Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells (2006) 3.02
Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer (2009) 2.62
NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood (2008) 2.54
FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol (2007) 2.47
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet (2013) 2.15
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood (2006) 2.10
Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A (2007) 2.08
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Retracted Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene (2005) 1.91
Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood (2004) 1.67
Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet (2007) 1.67
Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J (2007) 1.65
Short-term effects of particulate matter on total mortality during Saharan dust outbreaks: a case-crossover analysis in Madrid (Spain). Sci Total Environ (2011) 1.63
CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.63
Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res (2007) 1.60
Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther (2003) 1.58
Retracted Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood (2006) 1.49
Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. Blood (2013) 1.49
A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol Ther (2005) 1.48
Delayed diagnosis and complications of Fanconi anaemia at advanced age--a paradigm. Br J Haematol (2006) 1.48
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One (2009) 1.48
Report from the in vitro micronucleus assay working group. Mutat Res (2003) 1.47
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst (2003) 1.42
Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol Ther (2006) 1.39
Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles. Retrovirology (2010) 1.32
A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. J Med Genet (2006) 1.30
Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol (2005) 1.30
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood (2010) 1.26
Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res (2010) 1.24
Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res (2007) 1.24
Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids. J Virol (2002) 1.22
WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer (2007) 1.20
Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo. Blood (2009) 1.20
Retracted Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood (2004) 1.20
Restriction of foamy viruses by primate Trim5alpha. J Virol (2008) 1.19
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci U S A (2012) 1.19
Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood (2011) 1.18
Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res (2007) 1.18
The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J Biol Chem (2007) 1.18
Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther (2013) 1.16
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer (2009) 1.15
Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol (2007) 1.15
Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leuk Res (2007) 1.15
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One (2010) 1.15
Autologous human serum for cell culture avoids the implantation of cardioverter-defibrillators in cellular cardiomyoplasty. Int J Cardiol (2004) 1.14
Hematopoietic mobilization in mice increases the presence of bone marrow-derived hepatocytes via in vivo cell fusion. Hepatology (2006) 1.13
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther (2010) 1.11
EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep (2012) 1.10
Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. Hum Mol Genet (2002) 1.10
Quantification of miRNA-mRNA interactions. PLoS One (2012) 1.09
On the role of FAN1 in Fanconi anemia. Blood (2012) 1.07
Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther (2009) 1.07
MicroRNAs as cancer players: potential clinical and biological effects. DNA Cell Biol (2007) 1.07
A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood (2004) 1.05